Cancer Pain Management with Opioids

First-Line Opioid Selection

The National Comprehensive Cancer Network recommends pure opioid agonists with short half-lives, such as morphine, hydromorphone, fentanyl, and oxycodone, for cancer pain management as they can be more easily titrated than long half-life opioids 1, 2
Oral morphine is generally considered the standard first-line medication for opioid-naïve patients, with initial doses of 5-15 mg oral morphine sulfate or 2-5 mg intravenous morphine sulfate 1, 2
The American College of Physicians and other organizations support the use of oral morphine as a first-line opioid for cancer pain management 1, 3

Hydromorphone or oxycodone are effective alternatives to oral morphine, with potency ratios to oral morphine of 7.5:1 and 1.5-2:1, respectively 4, 5
Fentanyl transdermal patches should only be used after pain is controlled by other opioids, not for rapid titration, as recommended by the National Comprehensive Cancer Network 1, 2

Morphine should be avoided in patients with renal disease and hepatic insufficiency due to accumulation of morphine-6-glucuronide, an active metabolite, according to the National Comprehensive Cancer Network 1, 2
Fentanyl and buprenorphine are the safest opioids for patients with severe renal impairment, as stated by the European Society for Medical Oncology 6, 5

Opioid doses should be titrated to effect as rapidly as possible, with around-the-clock dosing and provision of breakthrough doses, as recommended by the European Society for Medical Oncology 7, 4
Oral administration is the preferred route for chronic opioid therapy, but continuous parenteral infusion may be necessary for patients who cannot take oral medications, according to the National Comprehensive Cancer Network 1, 2

Common opioid side effects include constipation, nausea, vomiting, drowsiness, cognitive impairment, confusion, hallucinations, and myoclonic jerks, which can be managed with laxatives, anti-emetics, major tranquilizers, and psychostimulants, as recommended by the European Society for Medical Oncology 7, 4
Constipation should be proactively managed with laxatives, and anti-emetics should be used for nausea and vomiting, according to the European Society for Medical Oncology 6, 7, 4

Anticonvulsants, such as gabapentin and pregabalin, and antidepressants, such as nortriptyline and duloxetine, can be added for neuropathic pain components, as recommended by the European Society for Medical Oncology 5
Non-opioid analgesics, such as acetaminophen and NSAIDs, can be combined with opioids for enhanced pain control, and radiotherapy can be effective for pain caused by bone metastases, according to the European Society for Medical Oncology 7, 8

When high-dose morphine provides inadequate pain control, rotation to an alternative strong opioid, such as hydromorphone, oxycodone, or fentanyl, is recommended, with calculation of the total 24-hour morphine dose and determination of the equianalgesic dose of the new opioid using conversion tables, as stated by the European Society for Medical Oncology 5

The National Comprehensive Cancer Network recommends oral morphine as the gold standard first-line opioid for cancer pain, with pure opioid agonists like morphine being preferred for their ease of titration 9
For patients already requiring short-acting narcotics every 4-6 hours, transition to around-the-clock extended-release formulations with rescue doses is the appropriate next step, according to the National Comprehensive Cancer Network 10
Morphine is substantially less expensive than transdermal fentanyl or branded long-acting oxycodone formulations, which is critical for a patient without pharmacy benefits, as stated by the National Comprehensive Cancer Network 9

The patient's current use of short-acting narcotics every 4-6 hours indicates opioid tolerance and readiness for long-acting formulations, according to the National Comprehensive Cancer Network 10

Transdermal fentanyl is explicitly NOT indicated for rapid opioid titration and should only be used after pain is controlled by other opioids in opioid-tolerant patients, as stated by the National Comprehensive Cancer Network 9
The National Comprehensive Cancer Network states fentanyl patches are reserved for patients with poor morphine tolerance, inability to swallow, or poor compliance—none of which apply to this patient 9
Transdermal fentanyl is significantly more expensive than oral morphine, making it cost-prohibitive for patients without pharmacy benefits, according to the National Comprehensive Cancer Network 9

Without pharmacy benefits, the cost differential between long-acting oxycodone and generic long-acting morphine preparations becomes the deciding factor when clinical efficacy is equivalent, as stated by the National Comprehensive Cancer Network 9

Calculate the patient's total 24-hour short-acting opioid requirement, then convert to equivalent long-acting morphine dose using standard conversion tables, as recommended by the National Comprehensive Cancer Network 9, 10
Provide immediate-release morphine for breakthrough pain at 10-15% of total daily dose, according to the National Comprehensive Cancer Network 10
Reassess pain control within 24-48 hours of initiating long-acting morphine and adjust the dose as needed, as stated by the National Comprehensive Cancer Network 10
Proactively manage constipation with stimulant laxatives starting simultaneously with opioid initiation, as recommended by the National Comprehensive Cancer Network 9, 10
Ensure adequate follow-up and access to prescribed medications despite lack of pharmacy benefits, according to the National Comprehensive Cancer Network 9